IRCT20201128049515N1RecruitingPhase 2
The efficacy and safety of Silymarin in chemotherapy-induced peripheral neuropathy (CIPN): a randomized double-blind clinical trial study
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 80
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to no limit (—)
- Sex
- All
Inclusion Criteria
- •Histologically confirmed diagnosis of cancer
- •At least 18 years of age
- •Having chemotherapy-induced peripheral neuropathy (CIPN).
Exclusion Criteria
- •Having a known disease predisposing to neuropathy, including diabetes, neuromuscular disease, vitamin B12 deficiency, amyloidosis, and connective tissue disease, a history of neurological diseases such as hereditary and acquired neuropathies
- •Unbearable side effects of the drug or drug reaction
- •Taking any antioxidant supplement in the last two months
- •Pregnancy, or breastfeeding
- •unwillingness to attend the study
Investigators
Similar Trials
Recruiting
Phase 3
Silymarin in multiple SclerosisTherapeutic effect of silymarin.IRCT20171220037977N1Esfahan University of Medical Sciences60
Not yet recruiting
Phase 2
Silymarin capsule in COVID-19COVID-19 disease.COVID-19U07.1IRCT20180103038199N10Mashhad University of Medical Sciences140
Completed
Phase 3
The effect of silymarin on methadone poisoningIRCT20210216050377N1Shahre-kord University of Medical Sciences64
Not yet recruiting
Phase 3
Effect of silymarin in inflammatory bowel diseaseK50-K52Inflammatory Bowel Disease.Noninfective inflammatory bowel diseaseIRCT20101107005123N3Mashhad University of Medical Sciences40
Completed
Phase 2
To evaluate the effectiveness of Silymarin (Livergol) on IL-6 levels and size of endometrioma lesionsIRCT20150905023897N5Vice chancellor for research Tarbiat Modares University60